Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes
The goal of this study is to learn how GLP-1 receptor agonist therapy affects muscle and bone health in older females over age 65 with type 2 diabetes. The main question it aims to answer is whether or not 6 months of GLP-1 RA therapy affects muscle strength. Participants will: * Receive GLP-1 RA therapy as part of their routine clinical care * Complete muscle strength assessments (hand grip strength, Timed Up and Go test) * Provide blood samples for bone turnover markers * Undergo bone mineral density testing
• Postmenopausal women aged 65 years or older
• Has type 2 diabetes
• Body Mass Index (BMI) ≥27 kg/m² to max 40kg/m2 (inclusive)
• Hemoglobin A1c \>7% within 3 months of the first visit.
• Willingness and ability to comply with all study procedures, including fasting requirements for certain visits.
• No osteoporosis confirmed on DEXA scan within 12 months
• Able to provide informed consent and participate in all study assessments